The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of the earliest studies dating back to the mid-2000s. Major limitations to autologous CAR-T cell therapy include complex logistics, high cost, concerns over toxicity, long manufacturing […]